20 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
in achieving our mission of expanding PEDMARQSI to patients across the globe who are at risk of suffering from cisplatin-induced ototoxicity,” said
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
11 Feb 20
PEDMARKTM1 is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children
2:17pm
are the culmination of many years of hard work, bringing us one step closer to achieving our mission,” said Rosty Raykov, chief executive officer of Fennec
424B3
o7duaztmamw 58v
21 Apr 14
Prospectus supplement
12:00am
424B3
frsy 0dla
4 Apr 13
Prospectus supplement
12:00am
POS AM
uq4x5g 1j
1 Apr 13
Prospectus update (post-effective amendment)
12:00am
8-K
f4hekc1czso
26 Aug 11
Adherex Announces Completion of Reverse Stock Split and Continuance to British Columbia
12:00am
424B3
63riqzs2hw mq40ce5
26 Aug 11
Prospectus supplement
12:00am
- Prev
- 1
- Next